Literature DB >> 8938701

Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy.

P Melacini1, A Vianello, C Villanova, M Fanin, M Miorin, C Angelini, S Dalla Volta.   

Abstract

This study aimed to describe myocardial involvement, respiratory impairment and pulmonary blood flow abnormalities in advanced-stage Duchenne muscular dystrophy (DMD). Twenty-one wheelchair-bound patients, aged from 10 to 24 yr, underwent electrocardiographic and echocardiographic examination, conventional spirometry, diurnal arterial blood gas analysis, and nocturnal polysomnography (SaO2 monitoring). Diagnosis was confirmed by neurological examination, dystrophin analysis at protein and DNA level. Patients were classified into two groups: group A normoxemic (14 cases) and group B with nocturnal hypoxemia (seven cases). Group A was further split into two subgroups, one without, and one with, left ventricular dilation (A1 = nine patients, end diastolic volume (EDV) = 51 ml m-2, ejection fraction (EF) = 56 per cent; A2 = five patients, EDV = 112 ml m-2, EF = 32 per cent; P < 0.05). Left ventricular regional wall motion abnormalities were found in 55, 40, and 43 per cent of groups A1, A2, and B patients respectively. Analysis of pulsed Doppler pulmonary data highlighted a significant reduction in corrected time to peak velocity in group B patients, when compared with control, A1, and A2 groups respectively. In group A, we observed a direct correlation between ejection fraction and corrected time-to-peak velocity. Two patterns of cardiac involvement may be recognized in advanced-stage DMD: left ventricular wall motion abnormalities and dilated cardiomyopathy. Doppler data which could suggest pulmonary hypertension may be observed in patients with dilated cardiomyopathy, and in patients with nocturnal hypoxemia. Therefore, in the management of advanced-stage DMD, a careful diagnosis of the heart-lung relationship should be performed, and both conventional treatment of heart failure and ventilatory therapy are necessary to improve the quality of life and survival in these patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938701     DOI: 10.1016/0960-8966(96)00357-4

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  35 in total

1.  Occult left ventricular dysfunction diagnosed by myocardial performance index in patients with limb girdle muscle dystrophy: A case control study.

Authors:  Rajashekar R Gurrala; Venkata Mb Alla; Wilbert S Aronow; Jai S Shankar; Meena K Angamutta; Krishna Lanka; Sundaram Challa; Chandra K Nair
Journal:  Int J Angiol       Date:  2007

2.  Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  Christopher Spurney; Reiko Shimizu; Lauren P Morgenroth; Hanna Kolski; Heather Gordish-Dressman; Paula R Clemens
Journal:  Muscle Nerve       Date:  2014-05-14       Impact factor: 3.217

3.  Sensorimotor control of breathing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  David P Burns; Arijit Roy; Eric F Lucking; Fiona B McDonald; Sam Gray; Richard J Wilson; Deirdre Edge; Ken D O'Halloran
Journal:  J Physiol       Date:  2017-10-09       Impact factor: 5.182

4.  Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.

Authors:  Maria C Vila; James S Novak; Margaret Benny Klimek; Ning Li; Melissa Morales; Alexander G Fritz; Katie Edwards; Jessica F Boehler; Marshall W Hogarth; Travis B Kinder; Aiping Zhang; Davi Mazala; Alyson A Fiorillo; Bonnie Douglas; Yi-Wen Chen; John van den Anker; Qi L Lu; Yetrib Hathout; Eric P Hoffman; Terence A Partridge; Kanneboyina Nagaraju
Journal:  J Pathol       Date:  2019-04-16       Impact factor: 7.996

5.  Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy.

Authors:  Eric Himelman; Mauricio A Lillo; Julie Nouet; J Patrick Gonzalez; Qingshi Zhao; Lai-Hua Xie; Hong Li; Tong Liu; Xander Ht Wehrens; Paul D Lampe; Glenn I Fishman; Natalia Shirokova; Jorge E Contreras; Diego Fraidenraich
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

7.  Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.

Authors:  Kitipong Uaesoontrachoon; James L Quinn; Kathleen S Tatem; Jack H Van Der Meulen; Qing Yu; Aditi Phadke; Brittany K Miller; Heather Gordish-Dressman; Ennio Ongini; Daniela Miglietta; Kanneboyina Nagaraju
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

8.  Mapping contrast agent uptake and retention in MRI studies of myocardial perfusion: case control study of dogs with Duchenne muscular dystrophy.

Authors:  William S Kerwin; Anna Naumova; Rainer Storb; Stephen J Tapscott; Zejing Wang
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-17       Impact factor: 2.357

9.  Severe cardiomyopathy in mice lacking dystrophin and MyoD.

Authors:  L A Megeney; B Kablar; R L Perry; C Ying; L May; M A Rudnicki
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

10.  Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?

Authors:  Michael D Puchalski; Richard V Williams; Bojana Askovich; C Todd Sower; Kan H Hor; Jason T Su; Nathan Pack; Edward Dibella; William M Gottliebson
Journal:  Int J Cardiovasc Imaging       Date:  2008-08-07       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.